IART Integra LifeSciences Holdings Corporation

NEUTRAL Impact: 4/10 PRESS-RELEASE
Horizon days Filed May 5, 2026 Processed 1mo ago Wire GlobeNewswire
Press release: leadership
Latest settled — T+20d ⚠ clustered
IART ▲ +18.53% at T+20d
NEUTRAL call ✓ call won +18.53% · α vs SPY +13.58% · entry $13.22 → $15.67
Next anchor: T+60d in 7w
Currently $17.77 · +34.42% from $13.22 entry
Entry anchored
May 5, 2026
via day open
T+1d
+5.90%
call +5.90% · α +4.52%
$14.00
settled 5w ago
T+5d
+4.16%
call +4.16% · α +2.18%
$13.77
settled 5w ago
T+20d
+18.53%
call +18.53% · α +13.58%
$15.67
settled 10d ago
T+60d
call — · α —
in 7w

Price Chart

Loading chart...

Executive Summary

Integra LifeSciences appointed Chairman Stuart Essig as President and CEO, effective May 1, 2026, replacing Mojdeh Poul who is leaving. The Board stated this is not an interim role and no CEO search will be initiated. Michael McBreen was also appointed Chief Commercial Officer. The leadership change comes amid ongoing operational and quality remediation efforts, but no financial details or guidance were provided.

Actionable Insight

Monitor the Q1 2026 earnings call later today for any strategic or financial updates from the new CEO. The appointment of a former CEO as permanent replacement without a search suggests urgency, but the lack of financial details limits immediate trading implications.

Key Facts

  • Stuart Essig appointed President and CEO, effective May 1, 2026, succeeding Mojdeh Poul
  • Essig will continue as Chairman; Board says no CEO search will be initiated
  • Michael McBreen appointed Chief Commercial Officer, a newly created role
  • Essig previously served as CEO from 1997 to early 2012 and as Chairman since 2012
  • No financial data, guidance, or strategic changes disclosed in the press release

Financial Impact

No financial figures disclosed; leadership change may signal strategic shift but no quantifiable impact provided

Risk Factors

  • Uncertainty around strategic direction under returning former CEO
  • Potential for further operational or quality issues not disclosed
  • Lack of financial guidance may disappoint investors expecting more detail

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
13% bullish (16 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3287434
8 reports for IART
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for IART — sortable, filterable
Type Now
May 8, 2026
5w ago
8-K
NEUTRAL ★ 2/10
$13.97 $14.11▲ +1.00%▲ +1.09%$17.77 (+27.20%)
May 5, 2026
5w ago
DEFA14A
NEUTRAL ★ 3/10
$13.22 $13.77▲ +4.16%▲ +2.18%$17.77 (+34.42%)
May 5, 2026
5w ago
8-K
NEUTRAL ★ 4/10
$13.22 $13.77▲ +4.16%▲ +2.18%$17.77 (+34.42%)
May 5, 2026
5w ago
8-K
BULLISH ★ 7/10
$13.22 $13.77▲ +4.16%▲ +2.18%$17.77 (+34.42%)
May 5, 2026
5w ago
Press Release
NEUTRAL ★ 4/10
$13.22 $13.77▲ +4.16%▲ +2.18%$17.77 (+34.42%)
May 5, 2026
5w ago
Press Release
MIXED ★ 6/10
$13.22 $13.77▲ +4.16%▲ +2.18%$17.77 (+34.42%)
Apr 20, 2026
7w ago
Press Release
BULLISH ★ 8/10
$11.16 $10.69▼ −4.21%▼ −5.12%$17.77 (+59.23%)
Feb 26, 2026
15w ago
8-K
MIXED ★ 6/10
$11.33 $9.89▼ −12.71%▼ −11.58%$17.77 (+56.84%)
Showing 8 of 8

US Market Status

Market Closed — Opens Mon (49h 9m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access